Top Headlines
Latest News
Analysis
Last week, researchers from Oregon Health & Science University reported that they had created embryonic stem cells via somatic cell nuclear transfer (SCNT), with a high enough efficiency to bring the creation of patient-specific embryonic stem cell lines into the realm of the possible.
Our Habitat for All Things Science
Psychiatry Searches for New Ways to Treat and Diagnose
Major depression affects more than 15 percent of the population at some point in their lives, and about 7 percent in any given year. Currently approved antidepressants are effective only about half the time – and even then, with a lag time of several weeks after a patient starts taking them.
READ MORE »- Sepsis Patients May Need Bigger Immune Response »
- No Working Kinase, but ErbB3 Acquires Oncogenic Mutations »
- Fungal Protein Points Way to New Breast Cancer Treatments »
- Short-lived Stem Cells Fight Brain Tumors, for a Time »
- Exhausted T Cells Can Rally Given Right Circumstances »
- Study Highlights New Target for Antidepressant Therapy »
- Adult Neurons Can Learn New Neurotransmitter 'Languages' »
- Study Could Lead to Inhibitors for Multidrug Molecular Pump »
- Weakened, Radioactive Listeria Poison Metastases, Not the Gut »
Upcoming conferences
Royalty Financing for Biotech and Medical Device Companies: How to Determine Eligibility and Take Advantage of this Unique Financing Opportunity
Opinion
- Biotech’s White Knight (aka Serial Cheater) Gets Prison Time, FinallyMay 03, 2013 | 3:41 PM | Posted by: Lynn Yoffee
- Where’s Superman When He’s Needed?April 30, 2013 | 10:07 AM | Posted by: Mari Serebrov
- Biopeople to Meet at BIO2013: Inside the World of Biotech’s Luminaries, Titans and BrainiacsApril 19, 2013 | 8:38 AM | Posted by: Lynn Yoffee
- Cancer Research Through Time: Cure Should’ve Been Wrapped up by 1985April 08, 2013 | 11:50 AM | Posted by: Anette Breindl
- ‘ImaginAb’ That! BioWorld Salutes ‘Overall Awesomeness’April 01, 2013 | 1:46 PM | Posted by: Jennifer Boggs
Featured Report
Word on the Street
The symptoms are kind of all over the place, we don’t have a target and the population is defined in so many different ways.
Kimberly McCleary President and CEO of the Chronic Fatigue and Immune Dysfunction Syndrome Association of America, on the difficulties of developing drugs for CFS